Daniel E Johnson

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8380675/publications.pdf

Version: 2024-02-01

63 papers	8,805 citations	201575 27 h-index	143943 57 g-index
63 all docs	63 docs citations	63 times ranked	16811 citing authors

#	Article	IF	Citations
1	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	4.3	3,122
2	Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nature Reviews Clinical Oncology, 2018, 15, 234-248.	12.5	1,789
3	Head and neck squamous cell carcinoma. Nature Reviews Disease Primers, 2020, 6, 92.	18.1	1,649
4	Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 4138-4143.	3.3	309
5	First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy. Cancer Discovery, 2012, 2, 694-705.	7.7	260
6	EGFR-targeted therapies in the post-genomic era. Cancer and Metastasis Reviews, 2017, 36, 463-473.	2.7	182
7	Targeting Stat3 Abrogates EGFR Inhibitor Resistance in Cancer. Clinical Cancer Research, 2012, 18, 4986-4996.	3.2	135
8	Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 1114-1119.	3.3	86
9	The ubiquitinâ€“proteasome system: opportunities for therapeutic intervention in solid tumors. Endocrine-Related Cancer, 2015, 22, T1-T17.	1.6	81
10	Prevention of Carcinogen-Induced Oral Cancer by Sulforaphane. Cancer Prevention Research, 2016, 9, 547-557.	0.7	77
11	Antiproliferative Mechanisms of a Transcription Factor Decoy Targeting Signal Transducer and Activator of Transcription (STAT) 3: The Role of STAT1. Molecular Pharmacology, 2007, 71, 1435-1443.	1.0	63
12	Caspaseâ€8 mutations in head and neck cancer confer resistance to death receptorâ€mediated apoptosis and enhance migration, invasion, and tumor growth. Molecular Oncology, 2014, 8, 1220-1230.	2.1	58
13	Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death. Molecular Cancer Therapeutics, 2009, 8, 2211-2220.	1.9	56
14	Fas stimulation induces RB dephosphorylation and proteolysis that is blocked by inhibitors of the ICE protease family. Journal of Cellular Biochemistry, 1997, 64, 586-594.	1.2	52
15	New Therapies in Head and Neck Cancer. Trends in Cancer, 2018, 4, 385-396.	3.8	50
16	Lack of toxicity of a STAT3 decoy oligonucleotide. Cancer Chemotherapy and Pharmacology, 2009, 63, 983-995.	1.1	47
17	Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for PIK3CA-altered head and neck cancer. Journal of Experimental Medicine, 2019, 216, 419-427.	4.2	46
18	Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients. Clinical Cancer Research, 2017, 23, 3072-3083.	3.2	45

#	Article	IF	Citations
19	An update: emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opinion on Emerging Drugs, 2018, 23, 283-299.	1.0	44
20	An ATRActive future for differentiation therapy in AML. Blood Reviews, 2015, 29, 263-268.	2.8	41
21	A protein network map of head and neck cancer reveals PIK3CA mutant drug sensitivity. Science, 2021, 374, eabf2911.	6.0	37
22	Systemic Administration of a Cyclic Signal Transducer and Activator of Transcription 3 (STAT3) Decoy Oligonucleotide Inhibits Tumor Growth without Inducing Toxicological Effects. Molecular Medicine, 2014, 20, 46-56.	1.9	34
23	ATR inhibition sensitizes HPVâ^' and HPV+ head and neck squamous cell carcinoma to cisplatin. Oral Oncology, 2019, 95, 35-42.	0.8	34
24	Targeting STAT3 in Cancer with Nucleotide Therapeutics. Cancers, 2019, 11, 1681.	1.7	32
25	Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer. Cancer Research, 2018, 78, 2383-2395.	0.4	31
26	STAT transcription factors in normal and cancer stem cells. Advances in Biological Regulation, 2014, 56, 30-44.	1.4	30
27	STAT3 Cyclic Decoy Demonstrates Robust Antitumor Effects in Nonâ€“Small Cell Lung Cancer. Molecular Cancer Therapeutics, 2018, 17, 1917-1926.	1.9	30
28	Src family kinases and the MEK/ERK pathway in the regulation of myeloid differentiation and myeloid leukemogenesis. Advances in Enzyme Regulation, 2008, 48, 98-112.	2.9	29
29	NSAID therapy for PIK3CA-Altered colorectal, breast, and head and neck cancer. Advances in Biological Regulation, 2020, 75, 100653.	1.4	25
30	Chemoprevention targets for tobacco-related head and neck cancer: Past lessons and future directions. Oral Oncology, 2015, 51, 557-564.	0.8	23
31	Therapeutic Implications of the Genetic Landscape of Head and Neck Cancer. Seminars in Radiation Oncology, 2018, 28, 2-11.	1.0	23
32	Targeting the JAK/STAT pathway in solid tumors. Journal of Cancer Metastasis and Treatment, 2020, 6, .	0.5	21
33	Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors. Cancer Biology and Therapy, 2014, 15, 1142-1152.	1.5	20
34	Single-agent obatoclax (GX15-070) potently induces apoptosis and pro-survival autophagy in head and neck squamous cell carcinoma cells. Oral Oncology, 2014, 50, 120-127.	0.8	20
35	Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma. Journal of Clinical Investigation, 2021, 131, .	3.9	20
36	Treatment of Fanconi Anemiaâ€“Associated Head and Neck Cancer: Opportunities to Improve Outcomes. Clinical Cancer Research, 2021, 27, 5168-5187.	3.2	18

#	Article	IF	Citations
37	Pathway-Specific Genome Editing of PI3K/mTOR Tumor Suppressor Genes Reveals that PTEN Loss Contributes to Cetuximab Resistance in Head and Neck Cancer. Molecular Cancer Therapeutics, 2020, 19, 1562-1571.	1.9	17
38	Signaling by cell surface death receptors: Alterations in head and neck cancer. Advances in Biological Regulation, 2018, 67, 170-178.	1.4	16
39	Investigational multitargeted kinase inhibitors in development for head and neck neoplasms. Expert Opinion on Investigational Drugs, 2019, 28, 351-363.	1.9	14
40	Alterations and molecular targeting of the GSK-3 regulator, PI3K, in head and neck cancer. Biochimica Et Biophysica Acta - Molecular Cell Research, 2020, 1867, 118679.	1.9	14
41	CYLD Alterations in the Tumorigenesis and Progression of Human Papillomavirusâ€“Associated Head and Neck Cancers. Molecular Cancer Research, 2021, 19, 14-24.	1.5	14
42	Targeting proliferation and survival pathways in head and neck cancer for therapeutic benefit. Chinese Journal of Cancer, 2012, 31, 319-326.	4.9	14
43	Biochemical Properties of a Decoy Oligodeoxynucleotide Inhibitor of STAT3 Transcription Factor. International Journal of Molecular Sciences, 2018, 19, 1608.	1.8	11
44	STAT3 decoy oligonucleotide-carrying microbubbles with pulsed ultrasound for enhanced therapeutic effect in head and neck tumors. PLoS ONE, 2020, 15, e0242264.	1.1	11
45	A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia. Leukemia and Lymphoma, 2018, 59, 2595-2601.	0.6	10
46	Targeting STAT3 with Proteolysis Targeting Chimeras and Next-Generation Antisense Oligonucleotides. Molecular Cancer Therapeutics, 2021, 20, 219-228.	1.9	10
47	Caspase-8 mutations associated with head and neck cancer differentially retain functional properties related to TRAIL-induced apoptosis and cytokine induction. Cell Death and Disease, 2021, 12, 775.	2.7	10
48	Caveolin-1 and Sox-2 are predictive biomarkers of cetuximab response in head and neck cancer. JCI Insight, 2021, 6, .	2.3	10
49	PDâ€Ł1 is upregulated via BRD2 in head and neck squamous cell carcinoma models of acquired cetuximab resistance. Head and Neck, 2021, 43, 3364-3373.	0.9	7
50	Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance. PLoS ONE, 2020, 15, e0227261.	1.1	6
51	Gene targets of sulforaphane in head and neck squamous cell carcinoma. Molecular Medicine Reports, 2019, 20, 5335-5344.	1.1	6
52	Genomic and Transcriptomic Alterations Associated with STAT3 Activation in Head and Neck Cancer. PLoS ONE, 2016, 11, e0166185.	1.1	4
53	NSAIDs Overcome PIK3CA Mutation-Mediated Resistance to EGFR Inhibition in Head and Neck Cancer Preclinical Models. Cancers, 2022, 14, 506.	1.7	4
54	Characterization of caspase proteases in cytokine-dependent myeloid progenitor cells using enzyme affinity labeling. Journal of Cellular Biochemistry, 1999, 73, 79-89.	1.2	3

#	Article	IF	Citations
55	Head and Neck Cancer among American Indian and Alaska Native Populations in California, 2009â€“2018. Cancers, 2021, 13, 5195.	1.7	3
56	When the Damage Is Done: Selecting Patients for Head and Neck Cancer Chemoprevention Trials. Cancer Prevention Research, 2017, 10, 489-490.	0.7	1
57	Phase 2 Study of Epigenetic Priming Using Decitabine Followed By Cytarabine As an Induction Regimen in Older Patients with Newly Diagnosed Acute Myeloid Leukemia. Blood, 2015, 126, 3739-3739.	0.6	1
58	The Herbicide Isoproturon Induces Activation-Induced Cytidine Deaminase Expression in Germinal Center B Cells. Blood, 2015, 126, 4816-4816.	0.6	0
59	A sensible approach to targeting STAT3-mediated transcription. Annals of Translational Medicine, 2016, 4, S57-S57.	0.7	0
60	Title is missing!. , 2020, 15, e0227261.		0
61	Title is missing!. , 2020, 15, e0227261.		0
62	Title is missing!. , 2020, 15, e0227261.		0
63	Title is missing!. , 2020, 15, e0227261.		0